Since late 2022, bad news in biotech has been nearly inescapable: flopped trials, slashed drug pipelines, bankruptcies and ...

Headed up by former Merck & Co. executive Roger Perlmutter, M.D., Ph.D., the biotech went on to secure a series of megarounds, with the most ambitious being a $517 million series B in 2022 and the ...

Since Dr. Vinay Prasad’s appointment as a key political voice within FDA, the tone of U.S. biotech policy has shifted from ...

Even with the layoffs, the unemployment rate for biotech in April was just 2.8%, according to the Bureau of Labor Statistics.

And just as China is developing its biotech sector, reports from the U.S. biotech hub of Cambridge and Boston are revealing layoffs and empty labs. A big strategy ...

Lately in the Boston life sciences industry, a Newton biotech cut 20% of its workforce, Novartis signed a deal with a Waltham ...

Biotech investment firm RA Capital has laid off staff at its internal startup incubator, highlighting the instability among VCs as the biotech industry struggles to right itself.

Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the ...

Massachusetts’ biotech workforce remained relatively stagnant last year, following several years of slowing growth, according to data released Tuesday by MassBioEd, an industry group focused on ...

The R&D tax credit isn’t the only area in which changes to tax policy could boost the biotech industry in Connecticut. Currently, the state’s R&D tax credit is available only to C Corporations.